Blast crisis
Drug research and approvals for blast crisis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 19 studies of blast crisis are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 1 approved and 0 open orphan designations naming it.
- Recruiting worldwide: 19
- Trials authorized in Canada: 0
- FDA orphan approvals: 1
- EU medicines: 0
- MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With…NCT07362225 · Not reported · MPN Research Foundation · starts Sep 26, 2025
- Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant…NCT07148947 · Phase 2 · University of Washington · starts Mar 2, 2026
- Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CMLNCT06757855 · Phase 1 / Phase 2 · Institute of Hematology & Blood Diseases Hospital, China · starts Jan 26, 2025
- A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)NCT06661915 · Phase 2 · National Cancer Institute (NCI) · starts Aug 14, 2025
- The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBPNCT06390306 · Not reported · Peking University People's Hospital · starts Jul 1, 2024
- MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG DosingNCT05794880 · Not applicable · Medical College of Wisconsin · starts May 1, 2023
- Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)NCT05322850 · Phase 1 / Phase 2 · University of Florida · starts Aug 16, 2022
- Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative NeoplasmsNCT05074355 · Phase 2 · University Health Network, Toronto · starts Nov 8, 2023
- Asciminib Roll-over StudyNCT04877522 · Phase 4 · Novartis Pharmaceuticals · starts Aug 30, 2022
Phase 2 9
- RituximabB-lymphocyte antigen CD20 binding agent
- CyclophosphamideDNA inhibitor
- CytarabineDNA inhibitor
- DoxorubicinDNA topoisomerase II alpha inhibitor
- MethotrexateDihydrofolate reductase inhibitor
- PonatinibBcr/Abl fusion protein inhibitor
- VincristineTubulin inhibitor
- PrednisoneGlucocorticoid receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
Phase 1 or earlier 10
- BosutinibTyrosine-protein kinase ABL inhibitor
- BusulfanDNA inhibitor
- Inotuzumab ozogamicinCD22 binding agent
- TacrolimusFK506-binding protein 1A inhibitor
- AldesleukinInterleukin-2 receptor agonist
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- AxitinibVascular endothelial growth factor receptor inhibitor
- BelinostatHistone deacetylase inhibitor
- AdavosertibSerine/threonine-protein kinase WEE1 inhibitor
- TroculeucelEnhanced NK cells
How its trials ended
138 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 46 whose ending is known, 22% met their primary endpoint, 4% missed it and 74% stopped early.
- Completed, result not reported6749%
- Ongoing2115%
- Stopped: other or unclear2115%
- Met its primary endpoint107%
- Stopped: enrollment or feasibility97%
- Status unknown43%
- Missed its primary endpoint21%
- Stopped: sponsor or business decision21%
- Stopped: safety11%
- Stopped: funding11%
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| May 10, 2001 | GleevecTreatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of… | Novartis Pharmaceuticals Corporation | Approved |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA